Nostrin-flox Mouse
Common Name
Nostrin-flox
제품 ID
S-CKO-10618
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-329416-Nostrin-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Nostrin-flox Mouse (카탈로그 번호 S-CKO-10618)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Nostrin-flox
품종 계통계통 ID
CKOCMP-329416-Nostrin-B6J-VA
유전자명
제품 ID
S-CKO-10618
유전자 별칭
Daip2, mDaIP2
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 2
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000041865
NCBI 전사체 ID
NM_181547
타겟 영역
Exon 4~5
유효 영역 크기
~1.9 kb
유전자 연구 개요
NOSTRIN, short for nitric oxide synthase traffic inducer, is a pleiotropic regulator of endothelial cell function. It interacts with endothelial nitric oxide synthase (eNOS), modulating its subcellular distribution and NO release [7]. It also participates in multiple pathways such as those related to cell proliferation, inflammation, and angiogenesis, thus being of great biological importance. Genetic models, especially knockout models, can be valuable for studying its functions.
In murine trophoblast cells, NOSTRIN levels increase during gestation. Precocious over-expression of NOSTRIN leads to increased trophoblast giant cell (TGC) formation and invasion, as it affects the G/F actin ratio and forms complexes with proteins like N-WASP, Dynamin, and Cdk1 [1]. In cirrhosis and acute-on-chronic liver failure (ACLF) models, hepatic Nostrin expression is elevated, and its knockdown in human umbilical vein endothelial cells (HUVECs) improves eNOS activity and reduces inflammation [2]. In a benign prostatic hyperplasia (BPH) mouse model, NOSTRIN expression is inhibited. Over-expressing NOSTRIN in prostate epithelial cells inhibits proliferation, oxidative stress, and inflammation, possibly through NF-κB signaling [3]. In colon cancer cell lines, NOSTRIN over-expression reduces cell invasion, colony formation, and stemness, while its knockdown enhances metastatic potential [4]. In acute kidney injury (AKI) patients, serum Nostrin levels are higher and are associated with in-hospital death, need for kidney replacement therapy, and lack of kidney function recovery [5]. In cirrhotic patients, Nostrin expression is increased, reducing eNOS activity and local NO generation, and blood Nostrin concentration may be a biomarker for disease severity [6]. In end-stage chronic kidney disease (CKD) patients, serum Nostrin levels are further increased compared to AKI patients, indicating impaired turnover [8]. In zebrafish and mice, NOSTRIN is necessary for proper vascular development, as it impacts endothelial tip cell migration and filopodia formation, and is involved in FGF-2-dependent Rac1 activation [9].
In conclusion, NOSTRIN plays diverse and crucial roles in multiple biological processes and disease conditions. Through model-based research, especially in KO/CKO mouse models or other loss-of-function experiments, its functions in processes like trophoblast differentiation, liver disease development, BPH, colon cancer progression, kidney injury and disease, and vascular development have been revealed. These findings contribute to understanding the underlying mechanisms of these diseases and may provide potential therapeutic targets.
References:
1. Chakraborty, Shreeta, Ain, Rupasri. 2018. NOSTRIN: A novel modulator of trophoblast giant cell differentiation. In Stem cell research, 31, 135-146. doi:10.1016/j.scr.2018.07.023. https://pubmed.ncbi.nlm.nih.gov/30086473/
2. Vairappan, Balasubramaniyan, Wright, Gavin, M, Sundhar, Ravikumar, T S. 2023. Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF. In European journal of pharmacology, 958, 176010. doi:10.1016/j.ejphar.2023.176010. https://pubmed.ncbi.nlm.nih.gov/37634841/
3. Li, Shoubin, Yu, Chunhong, Xiao, Helong, Sun, Zhanxin, Liu, Junjiang. 2024. NOSTRIN is involved in benign prostatic hyperplasia via inhibition of proliferation, oxidative stress, and inflammation in prostate epithelial cells. In Translational andrology and urology, 13, 2055-2069. doi:10.21037/tau-24-209. https://pubmed.ncbi.nlm.nih.gov/39434759/
4. Paul, Madhurima, Gope, Tamal Kanti, Das, Priyanka, Ain, Rupasri. 2022. Nitric-Oxide Synthase trafficking inducer (NOSTRIN) is an emerging negative regulator of colon cancer progression. In BMC cancer, 22, 594. doi:10.1186/s12885-022-09670-6. https://pubmed.ncbi.nlm.nih.gov/35642021/
5. Erfurt, Stefan, Lauxmann, Martin, Asmus, Katharina, Patschan, Daniel, Hoffmeister, Meike. 2024. Serum Nostrin-A risk factor of death, kidney replacement therapy and acute kidney disease in acute kidney injury. In PloS one, 19, e0299131. doi:10.1371/journal.pone.0299131. https://pubmed.ncbi.nlm.nih.gov/38603667/
6. Vairappan, Balasubramaniyan, Ts, Ravikumar, Ram, Amit Kumar, Mohan, Pazhanivel, Pottakkat, Biju. 2024. NOSTRIN is an emerging positive regulator of decompensated cirrhotic patients with portal hypertension. In Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 57, 427-435. doi:10.1016/j.dld.2024.08.050. https://pubmed.ncbi.nlm.nih.gov/39294044/
7. Zimmermann, Kirstin, Opitz, Nils, Dedio, Jurgen, Muller-Esterl, Werner, Oess, Stefanie. 2002. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. In Proceedings of the National Academy of Sciences of the United States of America, 99, 17167-72. doi:. https://pubmed.ncbi.nlm.nih.gov/12446846/
8. Latuske, Vivien, Erfurt, Stefan, Hoffmeister, Meike. 2025. End-stage chronic kidney disease affects serum Nostrin turnover. In Kidney & blood pressure research, , 1-10. doi:10.1159/000545521. https://pubmed.ncbi.nlm.nih.gov/40228481/
9. Kovacevic, Igor, Hu, Jiong, Siehoff-Icking, Ann, Hoffmeister, Meike, Oess, Stefanie. 2012. The F-BAR protein NOSTRIN participates in FGF signal transduction and vascular development. In The EMBO journal, 31, 3309-22. doi:10.1038/emboj.2012.176. https://pubmed.ncbi.nlm.nih.gov/22751148/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
